

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Uni-Bio Science Group Ltd.

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 0690)

ADDITIONAL INFORMATION ON DELAY IN PUBLICATION OF FINAL RESULTS FOR THE TWELVE MONTHS ENDED 31 DECEMBER 2015

Reference is made to the announcement of Uni-Bio Science Group Limited (“**Company**”) dated 31 March 2016 (“**Announcement**”). Unless otherwise stated, capitalised terms used herein shall bear the same meanings as defined in the Announcement.

As set out in the Announcement, among other things, the Company will update the shareholders and potential investors of the Company in relation to any further developments about the expected timeline of the publication of the 2015 Annual Results and the 2015 Annual Report. The Company will use its best endeavours to publish the 2015 Annual Results and despatch the 2015 Annual Report to the shareholders of the Company as soon as practicable, which based on the latest information available to the Board, the date of publication of the 2015 Annual Results is expected to be on or before 27 May 2016. The Board acknowledges that any delay in publishing the 2015 Annual Results will constitute a non-compliance of Rule 13.49(1) of the Listing Rules and any delay in despatch of the 2015 Annual Report will constitute Rule 13.46(2)(a) of the Listing Rules.

UNAUDITED FINANCIAL INFORMATION FOR THE TWELVE MONTHS ENDED 31 DECEMBER 2015

In order to provide additional information to the shareholders and potential investors of the Company for a better assessment of the most recent financial performance of the Group, the Board announces the Group’s unaudited consolidated financial information for the twelve months ended 31 December 2015 (the “**Year**”) as set out below. Shareholders and potential investors of the Company should note that the financial information contained in this announcement is only made with reference to the unaudited consolidated management accounts and information currently available to the Board, which have not been reviewed by the audit committee of the Board and have not been reviewed or audited by the auditors of the Company and may be subject to adjustment.

	Twelve months ended 31 December 2015 HK\$’000 (unaudited)	Twelve months ended 31 December 2014 HK\$’000 (unaudited)	Nine months ended 31 December 2014 HK\$’000 (audited)
Revenue	123,364	112,581	91,793
Cost of sales	(20,636)	(18,922)	(15,129)
Gross profit	<u>102,728</u>	<u>93,659</u>	<u>76,664</u>

* For identification purpose only

**NOTE:* Due to the change of financial year end from 31 March to 31 December on 26 November 2014, the annual results of 2014 only represents nine months of performance. In order for financial performances to be directly comparative, the Company listed out unaudited twelve months ended 31 December 2014 in the extract above.

During the Year, the Company (together with its subsidiaries, the “**Group**”) recorded a consolidated turnover of approximately HK\$123,364,000 representing an increase of 9.6% compared with approximately HK\$112,581,000 recorded in the twelve months ended 31 December 2014. During the Year, the RMB devalued against the HKD, therefore the sales growth adjusted for forex fluctuations (the “**normalized growth**”) is approximately 11.8%.

The Group’s topline normalized growth compares very favorably to the overall People’s Republic of China’s hospital drug sales growth of approximately 5.0%, according to the data from IMS Health Incorporated. The Group demonstrated strong financial and operational performance as a result of the implementation of a number of strategic initiatives including 1) well managed tenders led by its new Market Access department, 2) strengthening of its commercial platform, and 3) successful penetration into new growth provinces.

As at 31 December 2015, the Group had cash balances (including pledged deposits, and cash and cash equivalents) of approximately HK\$110,030,000 (unaudited).

The above financial information has not been reviewed by the audit committee of the Board and have not been reviewed or audited by the auditors of the Company and may be subject to adjustments. Shareholders and potential investors of the Company are advised to read the annual results announcement carefully when it is published.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Uni-Bio Science Group Limited
TONG Kit Shing
Chairman

Hong Kong, 6 April 2016

As at the date of this announcement, the Board comprises two executive Directors, namely, Mr. Tong Kit Shing (Chairman) and Mr. Kingsley Leung; and three independent non-executive Directors, namely, Dr. Carl Aslan Jason Morton Firth, Mr. Zhao Zhi Gang and Mr. Chow Kai Ming.